Loading...

US And Asian Expansion Will Unlock Pharmaceutical Market Potential

Published
30 Mar 25
Updated
07 Nov 25
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
-36.2%
7D
0.3%

Author's Valuation

CHF 78.3336.5% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on 07 Nov 25

Fair value Decreased 6.75%

SKAN: Leadership Transition And Confirmed Guidance Will Drive Future Earnings Momentum

Analysts have revised their price target for SKAN Group down from CHF 84 to CHF 78.33. They cited modestly slower revenue growth expectations, a slightly higher discount rate, and marginally lower profit margin forecasts.

Shared on 28 Aug 25

With no changes in key valuation metrics such as the discount rate (4.16%) and future P/E (28.70x), SKAN Group’s consensus analyst price target remains unchanged at CHF84.00. What's in the News SKAN Group AG confirmed its full-year 2025 earnings guidance, targeting sales growth in the mid-teens.

Shared on 01 May 25

Fair value Decreased 5.32%

Shared on 24 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 2.57%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.